Azzalure® celebrates its 10-year anniversary

Galderma announced that it is now 10 years since Azzalure^® (AbobotulinumtoxinA) was first approved in Europe for the treatment of glabellar lines in the UK.¹ Azzalure is approved in 72 countries worldwide and has been used for 40 million glabellar line treatments in Europe and the U.S. alone.^1,2

“We are delighted to reach this ten-year landmark and are looking forward to another decade of high patient and physician satisfaction,” said Patricia Ramos, Brand Manager - Medical Solutions, A&C & Prescription Divisions, Galderma UK & Ireland. “Azzalure is a toxin you can trust: it is made in the UK and has been used for more than 25 years in a clinical environment.”

Consistently high patient satisfaction levels, fast onset and the duration of results do not appear to diminish over multiple treatments.³ The median onset of action is around two to three days, while results can be seen as quickly as 24 hours after treatment with Azzalure.^1,3 The effects of the treatment can last up to five months, with a treatment interval of 5.9 - 6.5 months seen in one retrospective study.^1,3 Azzalure has a well-established safety profile, is well-tolerated and is supported by 24 studies in aesthetic indications in which more than 6,200 patients were enrolled.^1,3,4

 

References

1. Azzalure Summary of Product Characteristics, Galderma, September 2018. 
2. Data on File MA-39613. Azzalure is marketed as Dysport^® outside the EU.
3. Rzany, et al. Treatment of glabellar lines with botulinum toxin type A. JEADV 2010;24 (Suppl. 1), 1-14.
4. Data on File MA-39386.